Equities

Jiangsu Jibeier Pharmaceutical Co Ltd

688566:SHH

Jiangsu Jibeier Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.91
  • Today's Change-0.300 / -1.56%
  • Shares traded391.88k
  • 1 Year change-34.88%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7299901,225
Total Receivables, Net369226147
Total Inventory303332
Prepaid expenses2.164.312.52
Other current assets, total0.813.690.33
Total current assets1,1311,2571,406
Property, plant & equipment, net832552272
Goodwill, net------
Intangibles, net586061
Long term investments1266257
Note receivable - long term------
Other long term assets------
Total assets2,2101,9651,819
LIABILITIES
Accounts payable9110270
Accrued expenses875326
Notes payable/short-term debt206.760
Current portion long-term debt/capital leases------
Other current liabilities, total121928
Total current liabilities210181124
Total long term debt000
Total debt206.760
Deferred income tax3.253.40--
Minority interest5.585.906.31
Other liabilities, total868586
Total liabilities305276217
SHAREHOLDERS EQUITY
Common stock189187187
Additional paid-in capital1,0821,0421,021
Retained earnings (accumulated deficit)633459394
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,9051,6881,602
Total liabilities & shareholders' equity2,2101,9651,819
Total common shares outstanding189187187
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.